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Systematic review and meta›analysis of evidence for
increasing numbers of drugs in antiretroviral combination
therapy
Rachel Jordan, Lisa Gold, Carole Cummins, Chris Hyde
Abstract
Objective To assess the evidence for the effectiveness
of increasing numbers of drugs in antiretroviral
combination therapy.
Design Systematic review, meta›analysis, and
meta›regression of fully reported randomised
controlled trials. All studies included compared
quadruple versus triple therapy, triple versus double
therapy, double versus monotherapy, or monotherapy
versus placebo or no treatment.
Participants Patients with any stage of HIV infection
who had not received antiretroviral therapy.
Main outcome measures Changes in disease
progression or death (clinical outcomes); CD4 count
and plasma viral load (surrogate markers).
Search strategy Six electronic databases, including
Medline, Embase, and the Cochrane Library, searched
up to February 2001.
Results 54 randomised controlled trials, most of good
quality, with 66 comparison groups were included in
the analysis. For both the clinical outcomes and
surrogate markers, combinations with up to and
including three (triple therapy) were progressively and
significantly more effective. The odds ratio for disease
progression or death for triple therapy compared
with double therapy was 0.6 (95% confidence interval
0.5 to 0.8). Heterogeneity in effect sizes was present in
many outcomes but was largely related to the drugs
used and trial quality.
Conclusions Evidence from randomised controlled
trials supports the use of triple therapy. Research is
needed on the effectiveness of quadruple therapies
and the relative effectiveness of specific combinations
of drugs.
Introduction
In 1987 zidovudine was introduced for the treatment
of HIV infection. Since then there has been an escala›
tion in the number of antiretroviral agents. Sequen›
tially, treatment with two and then three drugs has
become rapidly accepted.1–5 Treatment with four or
more drugs has also been proposed.3 6
Influential clinical guidelines tend to be based on
individual selected clinical trials, often published as
conference abstracts.3 4 7 Early results from individual
studies can be unrepresentative.8 Support for the clini›
cal benefit of increasing drug combinations comes
from well conducted cohort studies,9–14 but the length
of follow up is still too short to assess the long term
clinical benefit of triple therapy.
Systematic reviews have examined questions about
the effectiveness of specific drugs and combinations or
have included trials with a mixture of patients who
have and have not received drug treatment.15–20 We car›
ried out a systematic review on the effectiveness of
increasing numbers of drugs used in combination. To
reduce the potential for confounding by established
drug resistance we looked only at those patients who
had not previously received antiretroviral therapy.
Methods
Search strategy and inclusion criteria
This review was conducted to the suggested
QUOROM guidelines standards.21 We looked for
randomised controlled trials of antiretroviral therapy
in HIV patients (up to the end of February 2001) in
Medline, the Cochrane Library, Embase, CINAHL,
PsycLIT, Healthstar, appropriate internet sites such as
AIDSTRIALS, and citation lists. We also contacted
pharmaceutical companies. There was no language
restriction. We included studies only if they included
patients who were HIV positive (any stage) and were
aged >12 years with less than six months’ previous
antiretroviral therapy or if less than 30% of patients
had previous therapy or if patients who had never had
therapy were reported separately. The accepted
interventions were any licensed (United Kingdom or
United States) antiretroviral drug (or combination)
compared with any other antiretroviral drug or
placebo or no treatment. We excluded studies if they
lasted less than 12 weeks.
We assessed studies for quality using a standard
checklist.22 Data were extracted by two independent
reviewers. We included and listed in the review those
trials that did not provide any useful measure of
variance or had no events, but the data from these trials
could not be used in the analyses.
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Data analysis
Data were collected on all relevant outcomes, with dis›
ease progression and deaths as clinical outcomes and
CD4 count and viral load as surrogate markers.
To take account of the large dropout rates but to
maximise the length of time in the trial, we measured
CD4 count and viral load at the longest time point
when at least half of the total number of patients in
each arm remained.
Meta›analysis
For continuous outcomes (CD4 count and viral load
change) we calculated the treatment effect for
individual trials as the treatment effect (that is, mean
change) minus the control effect. We calculated the
standard error of the weighted mean difference by
adding the variances of the change in outcome in both
groups and taking the square root. For triple therapy
we also present data on viral load as the proportion of
patients in whom concentrations of plasma virus
became too low to be detected ( < 50 copies per ml).
We pooled data using the inverse variance method of
weighting (for continuous outcomes) and the fixed
effects Peto method for event rates.23 Significance was
set at P < 0.05. We assessed statistical heterogeneity
using the ÷2 test.24 25 When there were several arms
within a trial that allowed more than one comparison
per arm we weighted the number of events and the
number of participants so that each participant was
used only once.
We explored heterogeneity using sensitivity and
subgroup analyses and fixed effects weighted
regression techniques (Stata 5.0 software), with the
covariates of trial duration, baseline CD4 count/viral
load, dropout rates, drug dose, specific drug or drugs
Antiretroviral drug comparisons included in analyses of clinical outcomes and surrogate markers
Trials
No of
comparisons Comparison
Monotherapy v placebo or no treatment
Koot,41 ACTG 116A,46 Kinloch›de›Loes,45 Evers,51 ISS 902,49 Concorde,42 DATRI
002, 50 VACS 298,37 38 ACTG 016,34 ACTG 019,32 33 EACGS,39 EACG 017,44
Fischl,26 Mannucci,43 NHF›ACTG 03636
18 Zidovudine v placebo or no treatment
Double therapy v monotherapy
Two nucleosides:
NUCB 3001(2),60 NUCA 3001(2)55 4 Zidovudine + lamivudine v zidovudine
NUCA 3001(2)55 2 Zidovudine + lamivudine v lamivudine
ACTG 30666 1 Zidovudine + lamivudine v stavudine
Protocol 34, 225›02,61 DELTA›1,58 59 ACTG 17557 3 Zidovudine + didnaosine v zidovudine
ACTG 17557 1 Zidovudine + didanosine v didanosine
Protocol 34, 225›02,61 DELTA›1,58 59 ACTG 175,57 M50003,62 Kaulen52 5 Zidovudine + zalcitabine v zidovudine
ACTG 17557 1 Zidovudine + zalcitabine v didanosine
ACTG 30666 1 Stavudine + lamivudine v stavudine
ACTG 30666 1 Didanosine + lamivudine v didanosine
QUATTRO77 1 Zidovudine + lamivudine v ZDV›Lam›Lov›Zalc*
Yarchoan53 1 Zidovudine + didanosine v ZDV›did*
ACTG 30666 1 Zidovudine + lamivudine v didanosine
HIV›NAT 00280 1 Stavudine + didanosine v didanosine
Nucleoside + protease inhibitor:
Vella56 1 Zidovudine + saquinavir v zidovudine
Vella56 1 Zidovudine + saquinavir v saquinavir
Lewi79 1 Zidovudine + indinavir v zidovudine
Lewi79 1 Zidovudine + indinavir v indinavir
Triple therapy v double therapy
Two nucleosides + non›nucleoside:
INCAS,68 Floridia69 2 Zidovudine + didanosine + nevirapine v zidovudine + didanosine
INCAS68 1 Zidovudine + didanosine + nevirapine v zidovudine + nevirapine
ACTG 26170 1 Zidovudine + didanosine + delavirdine v zidovudine + didanosine
ACTG 26170 1 Zidovudine + didanosine + delavirdine v zidovudine + delavirdine
ACTG 26170 1 Zidovudine + didanosine + delavirdine v didanosine + delavirdine
Study 00673 1 Zidovudine + lamivudine + efavirenz v efavirenz + indinavir
Protocol 0021 part II85 1 Zidovudine + lamivudine + delavirdine v zidovudine + lamivudine
Protocol 0021 part II85 1 Zidovudine + lamivudine + delavirdine v zidovudine + delavirdine
AVANTI›172 1 Zidovudine + lamivudine + loviride v zidovudine + lamivudine
Two nucleosides + protease inhibitor:
EARTH›175 1 Stavudine + lamivudine + ritonavir v zidovudine + didanosine
EARTH›175 1 Stavudine + lamivudine + ritonavir v zidovudine + zalcitabine
EARTH›175 1 Stavudine + lamivudine + ritonavir v stavudine + didanosine
PROAB 3001,81 PROAB 200276 2 Zidovudine + lamivudine + amprenavir v zidovudine + lamivudine
Study 00673 1 Zidovudine + lamivudine + indinavir v efavirenz + indinavir
Opravil82 1 Zidovudine + lamivudine + ritonavir v zidovudine + lamivudine
AVANTI›284 1 Zidovudine + lamivudine + indinavir v zidovudine + lamivudine
PISCES86 1 Zidovudine + zalcitabine + saquinavir v zalcitabine + saquinavir
PISCES86 1 Zidovudine + zalcitabine + saquinavir v zidovudine + zalcitabine
AVANTI›383 1 Zidovudine + lamivudine + nelfinavir v zidovudine + lamivudine
*Alternating therapy: ZDV=zidovudine; Lam=lamivudine; Lov=loviride; Zalc=zalcitabine; did=didanosine.
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(presence of protease inhibitors or zidovudine), change
in CD4/viral load (mean/median/change/end point),
sensitivity of the viral load assay, and blinding and con›
cealment of allocation.
We assessed publication bias visually using a funnel
plot and statistically using Egger’s and Begg’s tests
(Stata 5.0).
Results
Quantity, quality, and characteristics of trials
Out of over 2000 search “hits” we retrieved 700 papers
and finally included 90, which referred to 54 different
trials26–86 and 20 404 patients. The trials were generally
of good quality and randomised. Concealment of allo›
cation was confirmed in a third, most were double
blind, and participants in each arm were comparable
within trials. Over 80% of the participants were men,
with an average age ranging between 27 and 40 years.
More patients were asymptomatic than at any other
clinical stage, mean baseline CD4 counts ranged from
83›660 cells per ìl, and mean viral load ranged from
2.35 to 7.35 log copies per ml. The length of the trials
varied from 12 weeks to 4.8 years, although follow up
was not always clearly reported.
The table lists the comparisons available for the
analyses. Zidovudine was the only monotherapy
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Fig 1 Funnel plots of CD4 count results for monotherapy versus
placebo, double therapy versus monotherapy, and triple therapy
versus double therapy
ACTG 01634
ACTG 01932
ACTG 019(b)32
ACTG 019(c)33
ACTG 019(d)33
CONCORDE42
EACG 01744
EACGS39
Evers51
Fischl26
Kinloch-de-Loes45
Koot41
Mannucci43
NHF-ACTG 03636
VACS 29837
Total (95% CI)
c
2 =25.47, df=14, z=5.02
Study
15/360
19/457
17/453
7/541
15/549
267/877
24/167
11/495
4/47
24/145
0/39
6/29
13/69
4/92
38/170
464/4490
Monotherapy
36/351
19/214
19/214
8/274
8/274
284/872
33/162
22/489
7/51
45/137
4/38
7/23
12/71
6/101
48/168
558/3439
0.1 0.2 1 5 10
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Placebo
0.40 (0.23 to 0.71)
0.41 (0.21 to 0.83)
0.37 (0.18 to 0.75)
0.41 (0.14 to 1.20)
0.93 (0.39 to 2.25)
0.91 (0.74 to 1.11)
0.66 (0.37 to 1.16)
0.50 (0.25 to 0.99)
0.60 (0.17 to 2.08)
0.42 (0.24 to 0.71)
0.12 (0.02 to 0.90)
0.60 (0.17 to 2.10)
1.14 (0.48 to 2.70)
0.72 (0.20 to 2.58)
0.72 (0.44 to 1.18)
0.70 (0.60 to 0.80)
Peto odds ratio
(95% CI fixed)
Peto odds ratio
(95% CI fixed)
Fig 2 Effect of zidovudine monotherapy versus placebo on disease progression or death.
Figures are number of events/number of participants
ACTG 01634
CONCORDE42
DATRI 00250
Evers51
Kinloch-de-Loes45
Koot41
VACS 29837
Total (95% CI)
c
2 =3.23, df=6, z=5.13
Study
175
482
9
47
30
22
102
867
No of
participants
22.8 (138.4)
-99.0 (255.0)
672.0 (524.0)
212.0 (181.0)
650.0 (270.0)
313.6 (259.6)
-49.0 (293.0)
Mean (SD)
Monotherapy Placebo
144
468
13
51
29
18
106
829
No of
participants
-29.0 (85.7)
-142.0 (237.0)
502.0 (524.0)
203.0 (247.0)
513.0 (290.0)
296.6 (115.8)
-82.0 (196.0)
Mean (SD)
52.5 (27.672 to 77.328)
43.0 (11.706 to 74.294)
170.0 (-275.354 to 615.354)
9.0 (-76.284 to 94.284)
137.0 (-6.093 to 280.093)
17.0 (-103.954 to 137.954)
33.0 (-35.011 to 101.011)
46.856 (28.951 to 64.761)
Weighted mean difference
(95% CI fixed)
Weighted mean difference
(95% CI fixed)
Favours placebo Favours monotherapy
-100 -50 0 50 100
Fig 3 Effect of zidovudine monotherapy versus placebo on change in mean (SD) CD4 count (cells per ìl)
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compared with placebo or no treatment. The most
common double therapies were two nucleosides, most
which were compared against zidovudine or didanos›
ine monotherapy. Triple therapies were mainly based
on the currently advised pattern of two nucleosides
(usually zidovudine plus didanosine or lamivudine)
with the addition of a protease inhibitor or a
non›nucleoside. One trial compared quadruple
therapy (two nucleosides plus ritonavir plus saquinavir
at lower doses given to boost each other rather than as
a true full dose quadruple combination) and therefore
was not incorporated into the analyses.78 Other
unusual interventions (such as cyclical or intermittent
therapies) were not included in the analyses. We classi›
fied immediate versus deferred zidovudine as zidovu›
dine versus placebo.
Potential publication bias
We found no consistent visual or statistical evidence of
publication bias (that is, the tendency that small studies
are more likely to be published if they have significant
positive results) except for CD4 count for triple versus
double therapy, where there was a clear lack of small
studies with negative results (fig1). The limitations of
the techniques, particularly when there are few trials
and there is heterogeneity present, mean we cannot
exclude publication bias.
Main outcomes
Monotherapy compared with placebo
Fifteen trials compared monotherapy with
placebo.26 32–34 36–39 41–45 50 51 Compared with placebo,
zidovudine significantly reduced disease progression
or death (odds ratio 0.7, 95% confidence interval 0.6 to
0.8), although there was substantial heterogeneity (fig
2). Zidovudine also resulted in an improvement in CD4
count of 47 cells per ìl (29 to 65) with no important
heterogeneity (fig 3) and a viral load reduction of 0.56
log copies per ml (0.71 to 0.41) with some unexplained
heterogeneity (fig 4). The heterogeneity present in the
clinical outcome data (range of odds ratio 0.1›1.1, fig 2)
was in part explained by the variable duration of the
trials: as the trials increased in length zidovudine had a
smaller relative effect. At 152 weeks (about three years),
as in the Concorde trial,42 the beneficial effect of zido›
vudine was virtually eliminated (fig 5).
Double therapy compared with monotherapy
We found 14 trials that compared double therapy with
monotherapy (figs 6›8). 52 53 55–62 66 77 79 80 Double therapy
resulted in significantly better clinical outcomes than
monotherapy did (fig 6) (odds ratio for disease
progression/death was 0.6, 0.5 to 0.7). There was some
heterogeneity, but this seemed to be largely accounted
for by one large trial of protease inhibitors.79 Sensitivity
analysis in which we excluded this trial did not alter the
effect size or confidence intervals. In contrast with the
results for monotherapy the trial duration did not
explain the heterogeneity, despite ranging from six
months to three years.
Results for surrogate markers were significantly
better with double therapy than with monotherapy
(figs 7 and 8). Subgroup analyses showed that
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Fig 4 Effect of zidovudine monotherapy versus placebo on change in mean (SD) viral load (log copies per ml)
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Fig 5 Duration of trial and odds of disease progression or death
with zidovudine monotherapy versus placebo
ACTG 17557
ACTG 175(b)57
ACTG 175(c)57
ACTG 175(d)57
Delta-158
Delta-1(b)58
Lewi79
Lewi(b)79
M5000362
NUCA 300155
NUCB 300160
Protocol 34, 225-0261
Protocol 34, 225-02(b)61
QUATTRO77
Vella56
Yarchoan53
Total (95% CI)
c
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Fig 6 Effect of double therapy versus monotherapy on disease progression or death. Figures
are number of events/number of participants
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heterogeneity in the CD4 counts was wholly accounted
for by the presence of zidovudine or protease inhibitors
(fig 7), which suggests that combinations that contain
protease inhibitors may be more effective than other
double therapies and that monotherapy with zidovudine
is less effective compared with other monotherapies.
Heterogeneity was present in the analysis of viral load,
but exploratory analyses were not informative.
Triple therapy compared with double therapy
We found 12 trials of triple therapy compared with
double therapy (fig 9›12).68–70 72 73 75 81–86 Triple therapy
significantly improved clinical outcomes compared
with double therapy (odds ratio for disease
progression/death was 0.6, 0.5 to 0.8) (fig 9), although
most trials had few events. Only one large trial lasted
over a year, and this contributed most events.86 The
heterogeneity was attributable to one open label study
with few events.73 In a sensitivity analysis that excluded
this study we found no change in the estimates of effect
size. The results for the surrogate markers (CD4 and
viral load) were consistent with those for the clinical
outcomes, showing that triple therapy was significantly
better than double therapy, though there was substan›
tial heterogeneity in all analyses. Regression analyses
of both the CD4 count and the change in viral load
indicated that possible causes of this heterogeneity
were issues of quality (concealment of allocation and
non›blinding) and types of drugs used.
Other outcomes
Twenty six trials gave information on drug related with›
drawals.30 33 34 36 37 39 42–45 51 55 58 60 61 63 68 69 72 73 75 76 81 82 84 86
Dropout rates were higher with monotherapy than with
placebo but no different between double therapy and
monotherapy. The results of triple compared with dou›
01 ZDV in double and mono (that is, ZDV+drug v ZDV)
  ACTG 17557
  ACTG 175(b)57
  Delta-158
  Delta-1(b)58
  Kaulen52
  M5000362
  NUCA 300155
  NUCA 3001(b)55
  NUCB 300160
  Protocol 34, 225-0261
  Protocol 34, 225-02(b)61
  QUATTRO77
  Yarchoan53
Subtotal (95% CI)
Test for heterogeneity c 2 =7.46, df=12, P=0.81
Test for overall effect z=9.95, P<0.00001
02 ZDV in double only (that is, ZDV+drug 1 v drug 1 (or drug 2))
  ACTG 175(c)57
  ACTG 175(d)57
  ACTG 306(b)66
  ACTG 306(c)66
  ACTG 306(d)66
  NUCA 3001(c)55
  NUCA 3001(d)55
Subtotal (95% CI)
Test for heterogeneity c 2 =1.44, df=6, P=0.96
Test for overall effect z=0.89, P<0.4
03 ZDV in neither arm (that is, two drugs v one drug (any))
  ACTG 30666
  HIV-NAT 00280
04 ZDV + Indinavir (protease inhibitor) v ZDV
  Lewi79
05 ZDV + Indinavir v Indinavir (protease inhibitor)
  Lewi79
Total (95% CI)
Test for heterogeneity c 2 =157.05, df=23, P<0.00001
Test for overall effect z=16.24, P<0.00001
Study
66
67
435
426
43
129
24
27
54
59
61
29
16
1436
66
67
49
52
49
24
27
334
53
16
94
94
2027
No of
participants
1.9 (155.1)
-19.2 (133.1)
17.0 (223.0)
-2.0 (159.0)
205.0 (200.0)
502.5 (153.0)
32.0 (123.0)
40.0 (153.0)
80.0 (96.0)
157.4 (158.0)
177.9 (164.0)
40.0 (115.0)
27.0 (74.0)
1.9 (155.1)
-19.2 (133.1)
84.4 (127.4)
111.5 (111.1)
87.2 (107.8)
32.0 (123.0)
40.0 (153.0)
128.8 (151.4)
26.0 (62.0)
136.0 (72.0)
136.0 (72.0)
Mean (SD)
Double therapy Monotherapy
68
68
212
212
42
127
28
28
53
30
30
30
10
938
67
67
16
18
18
27
27
240
16
15
174
194
1577
No of
participants
-82.7 (178.9)
-82.7 (178.9)
-49.0 (97.0)
-49.0 (97.0)
141.0 (163.0)
423.6 (133.6)
-17.0 (119.0)
-17.0 (119.0)
-10.0 (182.0)
124.4 (125.0)
124.4 (125.0)
18.0 (118.8)
-15.0 (59.0)
-11.5 (178.3)
-11.5 (178.3)
48.1 (115.8)
89.7 (98.8)
89.7 (98.8)
26.0 (110.0)
26.0 (110.0)
48.1 (115.8)
76.0 (93.0)
0.0 (32.0)
123.0 (103.0)
Mean (SD)
84.6 (27.96 to 141.24)
63.5 (10.36 to 116.64)
66.0 (41.31 to 90.69)
47.0 (27.04 to 66.96)
64.0 (-13.48 to 141.48)
78.9 (43.73 to 114.07)
49.0 (-17.06 to 115.06)
57.0 (-15.62 to 129.62)
90.0 (34.71 to 145.29)
33.0 (-27.22 to 93.22)
53.5 (-7.28 to 114.28)
22.0 (-37.76 to 81.76)
42.0 (-9.50 to 93.50)
57.7 (46.33 to 69.06)
13.4 (-43.37 to 70.17)
-7.7 (-60.98 to 45.58)
36.3 (-30.72 to 103.32)
21.8 (-32.93 to 76.53)
-2.5 (-57.22 to 52.22)
6.0 (-58.37 to 70.37)
14.0 (-57.08 to 85.08)
10.13 (-12.27 to 32.54)
72.7 (2.84 to 142.56)
-50.0 (-106.02 to 6.02)
136.0 (120.69 to 151.31)
13.0 (-7.54 to 33.54)
63.74 (56.04 to 71.43)
Weighted mean difference
(95% CI fixed)
Weighted mean difference
(95% CI fixed)
Favours
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Favours double
therapy
-100 -50 500 100
Fig 7 Effect of double therapy versus monotherapy on change in mean (SD) CD4 count (cells per ìl)
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ble therapy were heterogeneous. Subgroup classification
of trials according to presence of protease inhibitors
suggested that there was no significant difference in
dropout rates between triple therapy without a protease
inhibitor and double therapy without a protease inhibi›
tor. Trials of therapies that contained a protease
inhibitor in the triple but not the double arm had
significantly higher withdrawals. The exception to this
was the PISCES trial,86 the only trial that included
saquinavir in the triple arm (fig 13). Only four trials gave
useful information regarding quality of life related to
health,27–29 47 71 and they had inconsistent results.
Discussion
Principal findings
This systematic review of combination therapy for
people with HIV showed a consistently and signifi›
cantly greater benefit for increasing numbers of drugs
up to, and including, triple therapy for clinical
outcomes and surrogate markers. Marked variation in
the results for many outcomes was greater than could
be accounted for by chance alone. When we
investigated the effects of potential confounders on the
results we found that the heterogeneity for mono›
therapy was largely explained by decreasing effective›
ness over time, which is consistent with the
development of drug resistance. For double and triple
therapy, the heterogeneity was mainly accounted for by
the drugs tested (possible greater effectiveness of
protease inhibitors and weaker effect of zidovudine)
and issues of quality (blinding and concealment of
allocation) for particular trials but was not always con›
sistent between different surrogate and clinical
outcomes. We found no published trials on the
effectiveness of true full dose quadruple therapy.
Strengths and weaknesses
HIV patients who have never received antiretroviral
drugs comprise only a part of clinical practice, but
establishment of the effectiveness of such treatment in
these patients is fundamental to understanding the
overall relative benefit of the drugs, and subsequent
treatment decisions are contingent on the initial
choice. Though choice of this study population
reduced confounding, other potential causes of clinical
heterogeneity were reflected in the results. Exploration
of heterogeneity with regression techniques suggested
that different drugs might explain some of the
variation. This conclusion must be tempered with cau›
tion as post hoc analyses are purely exploratory and
the techniques used are limited, with small numbers of
observations. Data on individual patients would allow
better exploration of the effect of patient characteris›
tics, although such techniques are usually too
expensive and time consuming.87 In addition, some of
these findings are based on surrogate end points and
should be confirmed by clinical end points, which are
less well reported in published trials. Data on adverse
events are difficult to interpret in the context of HIV
ACTG 30666
ACTG 306(b)66
ACTG 306(c)66
ACTG 306(d)66
Delta-159
Delta-1(b)59
HIV-NAT 00280
NUCA 300155
NUCA 3001(b)55
NUCA 3001(c)55
NUCA 3001(d)55
NUCB 300160
NUCB 3001(b)60
Protocol 34, 225-0261
Protocol 34, 225-02(b)61
QUATTRO77
Vella56
Vella(b)56
Total (95% CI)
c
2 =46.46, df=17, z=17.77
Study
45
51
46
46
179
108
16
33
30
30
33
25
14
59
61
28
10
10
824
No of
participants
-0.84 (0.79)
-1.07 (0.80)
-0.83 (0.74)
-0.83 (0.74)
3.51 (0.75)
3.66 (0.56)
-1.27 (0.92)
-0.99 (0.73)
-0.90 (0.69)
-0.90 (0.69)
-0.99 (0.73)
-1.20 (0.59)
-0.80 (0.49)
4.30 (1.00)
4.53 (1.02)
-0.78 (0.55)
-0.73 (0.75)
-0.73 (0.75)
Mean (SD)
Double therapy Monotherapy
16
16
18
18
125
125
15
31
31
30
30
23
14
30
30
27
17
19
615
No of
participants
-0.41 (0.62)
-0.41 (0.62)
-0.72 (0.74)
-0.72 (0.74)
4.45 (0.73)
4.45 (0.73)
-0.93 (0.65)
-0.25 (0.47)
-0.25 (0.47)
-0.42 (0.39)
-0.42 (0.39)
-0.30 (0.51)
-0.20 (0.42)
5.07 (1.01)
5.07 (1.01)
-0.73 (0.92)
-0.49 (0.44)
-0.10 (0.29)
Mean (SD)
-0.430 (-0.812 to -0.048)
-0.660 (-1.035 to 0.285)
-0.110 (-0.513 to 0.293)
-0.110 (-0.513 to 0.293)
-0.940 (-1.109 to -0.771)
-0.790 (-0.956 to -0.624)
-0.340 (-0.898 to 0.218)
-0.740 (-1.039 to -0.441)
-0.650 (-0.947 to -0.353)
-0.480 (-0.764 to -0.196)
-0.570 (-0.856 to -0.284)
-0.900 (-1.211 to -0.589)
-0.600 (-0.938 to -0.262)
-0.770 (-1.212 to -0.328)
-0.540 (-0.983 to -0.097)
-0.050 (-0.452 to 0.352)
-0.240 (-0.750 to 0.270)
-0.630 (-1.113 to -0.147)
-0.655 (-0.727 to -0.583)
Weighted mean difference
(95% CI fixed)
Weighted mean difference
(95% CI fixed)
Favours
monotherapy
Favours double
therapy
-1 0 1
Fig 8 Effect of double therapy versus monotherapy on change in mean (SD) viral load (log copies per ml)
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Fig 9 Effect of triple therapy versus double therapy on disease progression or death. Figures
are number of events/number of participants
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trials in which patient behaviour may differ from clini›
cal practice, and a full evaluation of adverse events
should include postmarketing surveillance. Despite a
rigorous search for trials, the possibility of publication
bias cannot be completely excluded.
Implications and future research
This systematic review provides new evidence that the
escalation of combinations of antiretroviral drugs up to
triple therapy is an effective strategy. Our results for the
relative effectiveness of monotherapy versus placebo
and double therapy versus monotherapy are consistent
with the results of smaller meta›analyses.19 20 Also, the
overall findings are supported by the results of cohort
studies.9–14 However, there is no fully published
evidence on the effectiveness of quadruple or higher
combinations.
Exploratory analyses of the variation in results
showed that differences resulted from the specific
drugs used. Both effectiveness and cost considerations
indicate that future work to clarify which triple combi›
nation is the most effective is as important as
investigating the effectiveness of quadruple or higher
combinations. As the number of drugs increases, qual›
ity of life and safety assume relatively greater
importance but are currently inadequately reported.
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Fig 10 Effect of triple therapy versus double therapy on change in mean (SD) CD4 count (cells per ìl)
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Fig 12 Effect of triple therapy versus double therapy on proportion of participants reaching
undetectable viral load. Figures are number of events/number of participants
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Better evidence is required. The exploratory analy›
ses of heterogeneity indicate that the design of future
trials must be more rigorous and less variable (for
example, in trial duration, test drugs, comparators, and
clinical stage at entry) and should not rely on surrogate
outcomes alone. The research community must
respond. There are still important questions to be
answered about the effectiveness of existing agents.
This may require publicly funded trials which should
be carried out within a clear well supported collabora›
tive framework.
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